Black Mamba Research
2 months
(5/x) Boehringer discontinued their vial product and Fresenius couldn't make enough vials to keep up with demand, $AMPH's share in this channel rose rapidly, boosting glucagon sales from ~$55mm in 2022 to ~$114mm in 2023. With Fresenius back, $AMPH should cede share